KalVista Pharmaceuticals, Inc. (KALV)
Largest Insider Buys in Sector
KALV Stock Price History Chart
KALV Stock Performance
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 …
Insider Activity of KalVista Pharmaceuticals, Inc.
Over the last 12 months, insiders at KalVista Pharmaceuticals, Inc. have bought $16.11M and sold $6.61M worth of KalVista Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at KalVista Pharmaceuticals, Inc. have bought $9.05M and sold $3.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Venrock Healthcare Capital Partners III, L.P. (10 percent owner) — $32.22M.
The last purchase of 29,747 shares for transaction amount of $437,281 was made by Venrock Healthcare Capital Partners III, L.P. (10 percent owner) on 2024‑02‑08.
List of Insider Buy and Sell Transactions, KalVista Pharmaceuticals, Inc.
| 2024-09-09 | Sale | CHIEF EXECUTIVE OFFICER | 7,352 0.0175% | $12.19 | $89,622 | -4.97% | ||
| 2024-08-23 | Sale | CHIEF DEVELOPMENT OFFICER | 1,916 0.0044% | $12.40 | $23,758 | -7.92% | ||
| 2024-08-23 | Sale | CHIEF MEDICAL OFFICER | 2,135 0.0049% | $12.40 | $26,474 | -7.92% | ||
| 2024-08-19 | Sale | CHIEF EXECUTIVE OFFICER | 14,215 0.0326% | $12.01 | $170,769 | -4.25% | ||
| 2024-08-19 | Sale | CHIEF DEVELOPMENT OFFICER | 7,102 0.0163% | $12.01 | $85,318 | -4.25% | ||
| 2024-08-19 | Sale | CHIEF MEDICAL OFFICER | 7,973 0.0183% | $12.01 | $95,782 | -4.25% | ||
| 2024-06-07 | Sale | CHIEF EXECUTIVE OFFICER | 7,465 0.0175% | $11.53 | $86,068 | +3.90% | ||
| 2024-05-20 | Sale | CHIEF EXECUTIVE OFFICER | 21,959 0.0515% | $11.76 | $258,337 | -0.08% | ||
| 2024-05-20 | Sale | CHIEF DEVELOPMENT OFFICER | 11,610 0.0273% | $11.76 | $136,586 | -0.08% | ||
| 2024-05-20 | Sale | CHIEF SCIENTIFIC OFFICER | 8,088 0.019% | $11.76 | $95,151 | -0.08% | ||
| 2024-05-20 | Sale | CHIEF MEDICAL OFFICER | 13,175 0.0309% | $11.76 | $154,997 | -0.08% | ||
| 2024-02-20 | Sale | CEO | 24,888 0.0736% | $14.11 | $351,289 | -13.15% | ||
| 2024-02-20 | Sale | CFO, CBO | 22,802 0.0674% | $14.11 | $321,846 | -13.15% | ||
| 2024-02-20 | Sale | CHIEF DEVELOPMENT OFFICER | 12,053 0.0356% | $14.11 | $170,124 | -13.15% | ||
| 2024-02-20 | Sale | CHIEF SCIENTIFIC OFFICER | 28,288 0.0833% | $14.07 | $397,929 | -13.15% | ||
| 2024-02-20 | Sale | CHIEF MEDICAL OFFICER | 14,295 0.0422% | $14.12 | $201,774 | -13.15% | ||
| 2024-02-14 | Sale | CEO | 58,356 0.158% | $15.01 | $875,883 | -16.53% | ||
| 2024-02-14 | Sale | CFO, CBO | 40,855 0.1106% | $15.01 | $613,205 | -16.53% | ||
| 2024-02-14 | Sale | CHIEF SCIENTIFIC OFFICER | 28,171 0.0763% | $15.01 | $422,827 | -16.53% | ||
| 2024-02-14 | Sale | CHIEF DEVELOPMENT OFFICER | 39,886 0.108% | $15.01 | $598,661 | -16.53% |
Insider Historical Profitability
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4824731 11.1644% | $11.35 | 23 | 0 | |
| InterWest Management Partners IX, LLC | 10 percent owner | 4619196 10.6887% | $11.35 | 1 | 0 | |
| NOHRA GUY P | director | 4343550 10.0509% | $11.35 | 1 | 0 | |
| ACMP IV LLC | 10 percent owner | 4343550 10.0509% | $11.35 | 1 | 0 | |
| Vivo Ventures VI, LLC | 10 percent owner | 4204562 9.7293% | $11.35 | 1 | 0 |
Institutional Investor Ownership
| Vr Adviser Llc | $74.12M | 14.62 | 6.25M | +52.7% | +$25.58M | 3.6 | |
| Suvretta Capital Management, LLC | $49.72M | 9.81 | 4.19M | +56.19% | +$17.88M | 2.1 | |
| Tang Capital Management, LLC | $48.93M | 9.65 | 4.13M | +19.91% | +$8.12M | 0.18 | |
| Frazier Life Sciences Management L P | $43.74M | 8.63 | 3.69M | +1.81% | +$777,695.79 | 1.98 | |
| Adage Capital Partners Gp L L C | $30.54M | 6.03 | 2.58M | +265.25% | +$22.18M | 0.06 |